BLR Stock Overview
BLIRT S.A. engages in the manufacture and sale of recombinant enzymes for the life science industry.
+ 1 more risk
Price History & Performance
|Historical stock prices|
|Current Share Price||zł14.05|
|52 Week High||zł17.80|
|52 Week Low||zł6.20|
|1 Month Change||51.40%|
|3 Month Change||84.87%|
|1 Year Change||-19.71%|
|3 Year Change||1,452.49%|
|5 Year Change||842.95%|
|Change since IPO||114.50%|
Recent News & Updates
|BLR||PL Biotechs||PL Market|
Return vs Industry: BLR exceeded the Polish Biotechs industry which returned -41.8% over the past year.
Return vs Market: BLR underperformed the Polish Market which returned -17.1% over the past year.
|BLR Average Weekly Movement||16.1%|
|Biotechs Industry Average Movement||7.0%|
|Market Average Movement||6.8%|
|10% most volatile stocks in PL Market||13.4%|
|10% least volatile stocks in PL Market||4.5%|
Stable Share Price: BLR is more volatile than 90% of Polish stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: BLR's weekly volatility has increased from 11% to 16% over the past year.
About the Company
BLIRT S.A. engages in the manufacture and sale of recombinant enzymes for the life science industry. It offers proteins and enzymes, such as proteinases, RNase inhibitors, polymerases, nucleases, ligases, and other proteins; and molecular biology reagents, including DNA and RNA extraction, PCR and real-time PCR, reverse transcriptions, and RNA related products. BLIRT S.A. was founded in 1994 and is headquartered in Gdansk, Poland.
BLIRT Fundamentals Summary
|BLR fundamental statistics|
Is BLR overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BLR income statement (TTM)|
|Cost of Revenue||zł5.68m|
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Aug 11, 2022
|Earnings per share (EPS)||0.43|
|Net Profit Margin||19.02%|
How did BLR perform over the long term?See historical performance and comparison
7.1%Current Dividend Yield
Is BLIRT undervalued compared to its fair value and its price relative to the market?
Valuation Score 1/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PB vs Industry
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: BLR (PLN14.05) is trading above our estimate of fair value (PLN4.69)
Significantly Below Fair Value: BLR is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: BLR is good value based on its Price-To-Earnings Ratio (32.5x) compared to the Polish Biotechs industry average (34.9x).
PE vs Market: BLR is poor value based on its Price-To-Earnings Ratio (32.5x) compared to the Polish market (10x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BLR's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: BLR is overvalued based on its Price-To-Book Ratio (9.3x) compared to the PL Biotechs industry average (3.8x).
How is BLIRT forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as BLIRT has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has BLIRT performed over the past 5 years?
Past Performance Score2/6
Past Performance Score 2/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BLR has a high level of non-cash earnings.
Growing Profit Margin: BLR's current net profit margins (19%) are lower than last year (34.3%).
Past Earnings Growth Analysis
Earnings Trend: BLR has become profitable over the past 5 years, growing earnings by 75.1% per year.
Accelerating Growth: BLR's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: BLR had negative earnings growth (-66%) over the past year, making it difficult to compare to the Biotechs industry average (-6.2%).
Return on Equity
High ROE: BLR's Return on Equity (28.5%) is considered high.
How is BLIRT's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: BLR's short term assets (PLN19.3M) exceed its short term liabilities (PLN4.8M).
Long Term Liabilities: BLR's short term assets (PLN19.3M) exceed its long term liabilities (PLN1.1M).
Debt to Equity History and Analysis
Debt Level: BLR has more cash than its total debt.
Reducing Debt: Insufficient data to determine if BLR's debt to equity ratio has reduced over the past 5 years.
Debt Coverage: BLR's debt is well covered by operating cash flow (1603092.6%).
Interest Coverage: BLR earns more interest than it pays, so coverage of interest payments is not a concern.
What is BLIRT current dividend yield, its reliability and sustainability?
Dividend Score 1/6
Future Dividend Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BLR's dividend (7.12%) is higher than the bottom 25% of dividend payers in the Polish market (2.63%).
High Dividend: BLR's dividend (7.12%) is low compared to the top 25% of dividend payers in the Polish market (7.73%).
Stability and Growth of Payments
Stable Dividend: Too early to tell whether BLR's dividend payments have been stable as they only just started paying a dividend.
Growing Dividend: Too early to tell if BLR's dividend payments are increasing as they only just started paying a dividend.
Earnings Payout to Shareholders
Earnings Coverage: With its high payout ratio (231.7%), BLR's dividend payments are not well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its high cash payout ratio (45582.5%), BLR's dividend payments are not well covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mr. Marian Popinigis has been the Chief Executive Officer at BLIRT S.A. since July 2018. He is President of the Management Board at BLIRT S.A. Mr. Popinigis is a Co-Founder of Mercor S.A. and serves as its...
Experienced Management: BLR's management team is considered experienced (2 years average tenure).
Experienced Board: BLR's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
BLIRT S.A.'s employee growth, exchange listings and data sources
- Name: BLIRT S.A.
- Ticker: BLR
- Exchange: WSE
- Founded: 1994
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: zł246.247m
- Shares outstanding: 17.53m
- Website: https://www.blirt.eu
Number of Employees
- BLIRT S.A.
- Trzy Lipy 3/1.38
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/05/28 00:00|
|End of Day Share Price||2022/05/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.